Outlook Therapeutics (OTLK) Net Cash Flow Growth (1y) (2016 - 2026)
Outlook Therapeutics (OTLK) Net Cash Flow Growth (1y) (2016 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Outlook Therapeutics |
63.14 Mn |
55.40 Mn |
-21,888.00 |
-150.13% |
| Date | Value |
|---|
| Mar 31, 2026 |
-150.13% |
| Dec 31, 2025 |
106.44% |
| Sep 30, 2025 |
95.22% |
| Jun 30, 2025 |
108.84% |
| Mar 31, 2025 |
-94.97% |
| Dec 31, 2024 |
29.23% |
| Sep 30, 2024 |
-65.71% |
| Jun 30, 2024 |
-53.27% |
| Mar 31, 2024 |
523.25% |
| Dec 31, 2023 |
-137.30% |
| Sep 30, 2023 |
-19.62% |
| Jun 30, 2023 |
69.39% |
| Mar 31, 2023 |
25.71% |
| Dec 31, 2022 |
-37.23% |
| Sep 30, 2022 |
-65.39% |
| Jun 30, 2022 |
-85.40% |
| Mar 31, 2022 |
-137.11% |
| Dec 31, 2021 |
899.04% |
| Sep 30, 2021 |
54.33% |
| Jun 30, 2021 |
-186.52% |
